LONG MINI FUTURE - NOVO-NORDISK B | Market Closed - Swiss Exchange 08:50:00 15/05/2024 pm IST | ||
| 0.88 CHF | +2.33% |
|
| 3 months | +23.94% | ||
| 6 months | +175.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 15/24/15 | 0.88 | +2.33% |
| 14/24/14 | 0.86 | +1.18% |
Delayed Quote Swiss Exchange
Last update May 15, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| MNOBJV | |
| ISIN | CH1290585475 |
| Date issued | 31/08/2023 |
| Strike | 566.3 kr |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 0.29 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.91 CHF |
|---|---|
| Lowest since issue | 0.215 CHF |
| Spread | 0.14 CHF |
| Spread % | 13.73% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
910
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.08%
- Stock Market
- Certificates
- MNOBJV Certificat
